Navigation Links
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
Date:11/1/2011

2010, net loss included non-cash, stock-based compensation expense of $1.3 million and $4.0 million, respectively.Cash and Investments:  As of September 30, 2011, Lexicon had $144.2 million in cash and investments, as compared to $164.8 million as of June 30, 2011 and $211.1 million as of December 31, 2010.  

Lexicon Conference Call:Lexicon management will hold a conference call to discuss its clinical development progress and financial results for the third quarter of 2011 at 11:00 a.m. Eastern Time today.  The dial-in number for the conference call is 888-220-1244 (within the US/Canada) or 706-679-5615 (international).  The conference ID for all callers is 20122666.  Investors can access a live webcast of the call at www.lexpharma.com.  An archived version of the webcast will be available on Lexicon's corporate website through November 29, 2011.

About LexiconLexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor StatementThis press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1031, LX1032, LX1033, LX2931, and LX4211, including characterizations of the results of and projected timing of clinical trials of such
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
2. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
3. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
4. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
5. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
6. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
7. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
8. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
9. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
10. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
11. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
(Date:8/29/2014)... , Aug. 29, 2014 Does your doctor know ... 800 doctors have recommended marijuana to the over 112,000 currently ... But the majority of the other roughly 20,300+ active physicians ... very little about it – even though a poll in ... adults say they have tried it. "With ...
(Date:8/29/2014)... Md. , Aug. 29, 2014  United Therapeutics ... the U.S. District Court for the District of ... favor in the company,s case against Sandoz, Inc. regarding ... Peter Sheridan ruled that U.S. Patent No. ... and enjoined Sandoz from marketing its generic product until ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4District Court Decision Received In Remodulin Patent Case 2
... 3 Glufosfamide and Phase 2 Glufosfamide Plus ... Gemcitabine Clinical Trials to be Presented, REDWOOD CITY, Calif., ... announced two presentations,regarding its oncology product candidate glufosfamide. The presentations,will ... held,September 23 to 27, 2007, at the International Conference Center ...
... First Hsp90 Inhibitor to Enter Registration Trials, HAYWARD, ... ) today announced that it has successfully,reached a binding ... the design of its TIME-1 clinical trial, a pivotal ... treatment for patients with,multiple myeloma. Through the FDA,s Special ...
Cached Medicine Technology:Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO) 2Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO) 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 2Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 4Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 5Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 6Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 7
(Date:8/30/2014)... The Truth about Six Pack Abs is a ... users some shocking foods that can burn belly fat, unique ... as well as some motivation secrets for successful fitness. , ... one unique trick that can help users reduce junk-food cravings. ... people might think, cardio exercise routines are not the best ...
(Date:8/30/2014)... Information supplied by insurance companies has ... prices to consumers in 2014. A group of ratess ... using the open system for adults at http://quotespros.com/life-insurance.html ... use this year can help the average person to ... and not from medical histories. The finder tool works ...
(Date:8/30/2014)... Denver, Colorado (PRWEB) August 30, 2014 ... a method that keeps anxiety and panic attacks under ... "Panic Away" program review describes this new ... help sufferers control panic attacks and overcome general anxiety ... popular and successful is the fact that it can ...
(Date:8/30/2014)... New York, NY (PRWEB) August 30, 2014 ... for authentic U.S. Open Tennis Championship tickets ... their customer appreciation promo/coupon code US-OPEN-2014 for all day ... (GA) seats and group sales for this prestigious Grand ... schedule is below: , 8/30/14 , US Open Tennis ...
(Date:8/30/2014)... VA (PRWEB) August 30, 2014 Seniors Guide, ... articles recently that focus on Alzheimer’s Disease, Dementia, and ... revealed to the public of being diagnosed with the Alzheimer’s, ... latest movie, “I’ll Be Me”. The movie, out on ... while focusing on his diagnosis of the disease – which ...
Breaking Medicine News(10 mins):Health News:Truth about Six Pack Abs Review Reveals Unique Method to Eliminate Stubborn Stomach Fat 2Health News:Term Life Insurance Rates Now Found Nationally by New Insurer Finder Tool 2Health News:Panic Away Review Reveals New Natural Remedy for Anxiety Patients 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2
... in a gene called FGFR2 could accelerate the development ... uterine cancer. Researchers at Washington University School of Medicine ... (TGen); the Wellcome Trust Sanger Institute, which is part ... Medicine reported the findings in the May 21, 2007, ...
... new study has shown the severe repercussions of high-fat food combined ... on liver and other vital organs. ,The study ... at Saint Louis University. ,As part of the study, ... a diet that was 40 percent fat and replete with high ...
... A nationwide study has been launched in US to determine ... and lorazepam, is more effective. ,Childhood seizures ... seizures can lead to brain damage or even death ... two drugs currently prescribed to tackle emergency situations - ...
... research has found that parents can foresee their children's exam ... ,The University of Bath study suggests that English and ... , ,Students with longer ring fingers are more likely ... ring fingers are said to be more proficient at literacy. ...
... demand. Two experts in this weeks BMJ debate whether presumed ... is evidence to the contrary is the answer. ... organ donation, yet only 23% have registered their wish to ... the British Medical Association. ,Research indicates that countries ...
... is widely consumed beverage and is regularly investigated and ... cancer to heart disease. Among its complex effects on ... linked to lower insulin and uric acid levels on ... suggest that coffee consumption may affect the risk of ...
Cached Medicine News:Health News:Gene Discovery Lays Groundwork for Targeted Therapies for Endometrial Cancer 2Health News:Gene Discovery Lays Groundwork for Targeted Therapies for Endometrial Cancer 3Health News:High-fat and Sugary Diet Severely Damage Liver and Other Vital Organs 2Health News:Pediatric Seizure Study Underway in US to Decide Between Diazepam and Lorazepam 2Health News:Pediatric Seizure Study Underway in US to Decide Between Diazepam and Lorazepam 3Health News:Pediatric Seizure Study Underway in US to Decide Between Diazepam and Lorazepam 4Health News:Fingers of Kids can Predict Their Performance in Exams 2Health News:Is Presumed Consent the Answer to Organ Shortages? 2Health News:Four Cups of Coffee a Day may Cut Down the Risk of Gout 2Health News:Four Cups of Coffee a Day may Cut Down the Risk of Gout 3
The workhorse electric system....
... Knife with BD Xstar Blade includes a ... the blade in prodedure and handling. ... a grind-less process for manufacturing surgical blades. ... and consistency. The arch style, single-bevel ...
... Safety Knife with BD Xstar Blade includes ... protects the blade in prodedure and handling. ... on a grind-less process for manufacturing surgical ... sharpness and consistency. The arch style, ...
... BD Safety Knife with BD Xstar Blade ... that protects the blade in prodedure and ... based on a grind-less process for manufacturing ... outstanding sharpness and consistency. The arch ...
Medicine Products: